The reduction of user-fee funded positions in the FDA's FY 2026 budget request could foreshadow its approach to the upcoming user fee program reauthorizations. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
